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INTRODUCTON 
Seizures are the most common neurologic disorder in children. [1] 
A seizure is a sudden change in behaviour caused by electrical 
hypersynchronization of neuronal networks in the cerebral cortex. [2] 
Epilepsy can be defined as: (when any of the following exist): [2] 
 At least 2 unprovoked (or reflex) seizures occurring greater than 24 
hours apart. 
 1 unprovoked (or reflex) seizure and a probability of further seizures 
similar to the general recurrence risk after two unprovoked seizures 
(e.g.≥60%) occurring over the next 10 years. Examples: remote 
structural lesions such as stroke, CNS infection, or traumatic brain 
injury. 
 Diagnosis of an epilepsy syndrome. 
The second criterion emphasizes the use of neuroimaging and EEG 
in the evaluation of patients with a first-time seizure (added by the 
ILAE working group in 2014) 
 
Acute symptomatic seizure[3]: A seizure that occurs at the time of a 
systemic insult or in temporal association with a documented brain insult. 
Examples: metabolic abnormalities/ drug withdrawal/ stroke/ acute head 
injury/ encephalitis.  
The time period within which a seizure may be called as an acute 
symptomatic has not been clearly defined. As per a consensus panel 
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recommendation, the following are considered: 
●Within 1 week of stroke/ traumatic brain injury/ intracranial surgery/ 
anoxic encephalopathy 
●At first identification of a subdural hematoma 
●During the active phase of a CNS infection 
●Within 24 hours any severe metabolic derangement  
Acute symptomatic seizures generally carry a low risk for future epilepsy 
compared with unprovoked seizures.  
Unprovoked seizure [3]-It refers to a seizure of any unknown etiology as 
well as one that occurs in relation to a pre-existing brain lesion or a 
progressive nervous system disorder. 
Those unprovoked seizures that are determined to be due to an 
underlying brain lesion or disorder can also be called as remote 
symptomatic seizures [3]. The risk of future epilepsy is high compared with 
acute symptomatic seizures. 
Reflex seizures [4] - those that occur secondary to sensory stimulus (e.g. 
flashing lights) 
Status epilepticus [4] is defined as “continuous seizure activity or 
recurrent seizure activity without regaining of consciousness lasting for 
more than 5 minutes” 
During a seizure, blood flow to the brain is increased. There is an 
increase in the consumption of oxygen and glucose, and production of 
carbon dioxide and lactic acid. In early stages child may have tachycardia, 
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hypertension, stress hyperglycemia ,and sometimes hypoxemia. If these 
seizures are prolonged, it may lead to permanent neurologic damage to the 
developing brain . The child may also have lactic acidosis, rhabdomyolysis, 
hyperthermia, and hypoglycaemia. Hence, immediate Airway management 
and seizure termination are the most important initial priorities in children 
with active seizure activity. 
Classification of seizures: 
Seizures are broadly classified as : 
1) Generalized   
2) Focal (previously known as partial) 
GENERALIZED SEIZURES: 
In generalized seizures, there is involvement of both the cerebral 
hemispheres and alteration in the level of consciousness. They may be 
either convulsive or nonconvulsive. Motor involvement( in convulsive 
type), is usually bilateral.  
The following are classified under Generalized Type: [1] [5] 
1) Tonic-Clonic (grand mal epilepsy): 
A tonic phase for 30 seconds characterised by uprolling of eyes, tongue 
bite, froth from mouth & bladder/bowel incontinence followed by 
Clonic movements of all limbs 
2) Tonic: Only tonic phase without clonic component  
3) Clonic: Clonic movement of all limbs 
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4) Myoclonic: Sudden jerky violent contractions of axial and 
appendicular muscles 
5) Atonic: sudden loss of  muscle tone and consciousness 
6) Absence (petit mal epilepsy): Brief periods of unconsciousness (30 
to 60 sec) without associated motor involvement. 
FOCAL SEIZURES: [4] 
1) Focal seizures without impairment of consciousness (simple partial) 
usually present as sensory seizures (auras) or motor seizures 
(tonic/clonic/atonic). 
2) Focal seizures with impairment of consciousness (complex partial) 
are associated with automatisms and are usually preceded by aura. 
SPECIFIC EPILEPSY SYNDROMES: [1] [4] 
 Benign rolandic epilepsy, (age group of 3 to 10 years) is 
characterised by waking up in the middle of the night owing to a 
simple partial seizure. EEG shows centrotemporal spikes. No therapy 
is needed unless these seizures are frequent. 
 Infantile spasms (West’s syndrome) (age group of 4 to18 month) 
presents as sudden spasmodic jerking contractions of the head, trunk 
and extremities in clusters. Intellectual disability and tuberous 
sclerosis may be associated. EEG shows hypsarrhythmic pattern. 
ACTH, prednisone, sodium valproate, topiramate, vigabatrin (in 
tuberous sclerosis) are used in treatment. 
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 Lennox-Gastaut syndrome (age group 2 to 10 years) is characterized 
by a triad of developmental delay, multiple seizure types and the 
characteristic EEG (irregular, 1-2 Hz spike and slow waves with 
polyspike bursts). A combination of tonic, myoclonic, atonic, and 
absence seizures may occur that are intractable. Sodium valproate, 
felbamate, lamotrigine, topiramate, and ketogenic diet are used in 
treatment 
 Juvenile myoclonic epilepsy (age group of 12-18 years) is 
characterised by myoclonic jerks on awakening (tonic/clonic or 
absence seizures may also occur).EEG has characteristic fast spike 
and wave discharges pattern. Sodium valproate, lamotrigine, 
topiramate, and zonisamide are used in treatment. 
CAUSES OF SEIZURES: [1] 
 Selected important causes for seizures in children include : 
 Infectious causes: 
o Meningitis/Encephalitis 
o Brain abscess 
o Neurocysticercosis 
o Febrile seizures 
 Neurologic or developmental: 
o Congenital anomalies 
o Birth injury 
o Hypoxic-ischemic encephalopathy 
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o Degenerative cerebral disease 
o Neurocutaneous syndromes 
o VP shunt malfunction 
 Metabolic causes:  
o Hypoxia/ Hypercarbia 
o Hypocalcemia/ Hypomagnesemia 
o Hypoglycemia 
o IEM 
o Pyridoxine deficiency 
 Traumatic or vascular: 
o Stroke 
o Head trauma 
o Cerebral contusion 
o Intracranial haemorrhage 
o Child abuse 
 Drugs and Toxins 
 Oncologic 
 Idiopathic  
SEIZURE MIMICS IN CHILDREN: 
Whenever a child presents with a seizure, the most important part is 
to differentiate whether it is a true seizure or a seizure mimic. Usually there 
is no postictal phase following these events unlike true seizures. 
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Few important causes include: [1] [4] 
 Disorders associated with altered consciousness: 
o Apnea 
o Syncope(neutrally mediated & cardiac) 
o Breath-holding spells 
o Migraine 
o Cardiac dysrhythmias 
 Paroxysmal movement disorders: 
o Acute dystonia 
o Pseudo seizures 
o Benign sleep myoclonus 
o Spasmusmutans 
o Shuddering attacks 
o Tic disorders 
 Sleep disorders: 
o Sleepwalking 
o Narcolepsy 
o Night terrors 
 Psychologic disorders 
o ADHD 
o Hysteria 
o Hyperventilation 
o Panic attacks 
 Gastroesophageal reflux (Sandifer’s syndrome) 
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DIAGNOSIS:[1] 
LABORATORY TESTING:  
Basic laboratory testing for a child presenting with seizure should include:  
o Glucose levels 
o Serum electrolytes 
o Calcium/ionized calcium 
o Total/differential count 
o Sepsis screening (in selected cases) 
o Metabolic profile (in selected cases) 
o Lumbar puncture ( in neonatal seizures, in those who 
present with altered mental status, meningeal signs, or 
have a prolonged postictal period) 
NEUROIMAGING: 
 CT scan (in focal seizures/ Hydrocephalus/raised ICP/ 
neurocutaneous syndromes/trauma etc) 
 MRI of the brain is much more sensitive than a CT scan (detection of  
vascular malformations and certain tumors). 
ELECTROENCEPHALOGRAPHY : 
EEG is needed in an acute setting only for children presenting with 
refractory seizures and in whom nonconvulsive status epilepticus is strongly 
suspected. An otherwise well child can be subjected to EEG as an 
outpatient.  A normal EEG does not always rule out an epilepsy or an 
abnormal EEG does not always indicate epilepsy. 
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MANAGEMENT OF STATUS EPILEPTICUS:[6] 
The first line management always should be focussed on stabilization 
of the airway, breathing, circulation (ABC) and additionally stopping the 
seizure activity. Keeping the airway open, administering oxygen therapy, 
supporting ventilation , securing  an intravenous line, protecting the patient 
from self trauma are the initial key steps in management. 
Algorithm for the management of status epilepticus: 
Step 1: ABCs stabilization, establishing IV access, 
 IV glucose/ calcium/ pyridoxine ( in neonates and infants) 
Step 2:Lorazepam 0.1 mg/kg IV or  
Diazepam 0.2mg/kg IV 
If no iv access, consider diazepam 0.5mg/kg PR or buccal/nasal/IM 
midazolam 0.2mg/kg .If iv access still not available, intraosseous 
access could be tried 
Step 3: Repeat one more dose of Lorazepam / diazepam(5-10 min) 
Step 4: Consider Phenytoin 20mg/kg or fosphenytoin 20 PE(phenytoin 
equivalent)/kg IV (30 min) 
Step 5: IV Valproate (1:1 diluted NS 20-40 mg/kg over 1-5 min; if required 
continuous infusion at a rate 5mg/kg/hr can be given) 
     OR 
Phenobarbitone 20 mg/kg IV (Reassess airway/consider intubation if the 
airway is compromised/ respiratory depression develops) 
Step 6:  Transfer to ICU 
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Continuous infusion of  midazolam (loading dose 0.2mg/kg followed 
by 0.1 mg/kg/hr; increase every 15 min upwards by 0.05 mg/kg/hr till 
control to a maximum of 2 mg/kg/hr) or propofol /pentothal infusion 
Step 7: General anaesthesia 
LONG TERM TREATMENT:[1] 
The choice and duration of AEDs depends on multiple factors like 
the age of the child, the type of seizure, the risk of recurrence, and other 
predisposing factors. Those children with recurrent episodes of seizures 
need long term treatment with multiple antiepileptic drugs. 
The ideal anticonvulsant for a child should be individualised: 
1.The drug should be effective against the particular type of seizure. If 
multiple drugs are effective, the drug that is least toxic should be used. 
2. Single drug that is effective is started at the lowest dose. 
3.If seizures are well controlled, the same drug can be continued till a 
steady state is achieved, probably 5 times the t-half of the drug  
4. If seizures are not controlled, the dose of same AED can be increased 
until control is achieved or any unacceptable side effects occur. 
5. A second drug can be added if seizure control is poor and once they 
are controlled, the first drug can be slowly eliminated in order to 
maintain the child on monotherapy  
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 Those children who present with first episode unprovoked seizure 
who are otherwise well are scheduled for EEG and treated as out-
patients provided warnings signs/symptoms are explained. Most of 
these children do not require anticonvulsant therapy on long term.  
 Studies have shown that most of the recurrences of seizures are seen 
in the first 2 years after the initial episode and the chances of 
recurrences are more in those with abnormal EEG than those with 
normal EEG. 
 The decision to start antiepileptic drug therapy and the choice of the 
agent should be made on the basis of associated factors like the 
chance of recurrences /any psychosocial implications against the side 
effects of drug therapy( changes in behaviour/ intelligence)  and 
requires the consultation with a neurologist.  
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Approach to a child with suspected seizure disorder: [4] 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIRST EPISODE SEIZURE: 
1) History & physical examination 
2) Blood sugar, calcium and other 
metabolic studies 
3) EEG/CT/MRI/CSF analysis 
ABNORMAL 
SYMPTOMATIC SEIZURES: 
-Treat the cause ( eg: 
hypoglycaemia/meningitis) 
-AEDs if necessary 
NORMAL EXAMINATION 
AND INVESTIGATIONS WITH: 
-Isolated first episode seizure 
-Normal EEG 
-No family history 
 
1) Observation 
2) Continuous drug therapy- 
not needed 
3) Rescue medications if 
seizures had last for more 
than 5 min 
EEG/NEUROIMAGING 
ABNORMALITY: 
- Start Antiepileptic drugs 
- Follow up 
GOOD CONTROL: 
1) Regular follow up 
2) Monitor drug levels & toxicity 
3) EEG 
POOR CONTROL: 
1) Hospitalization 
2) Continuous EEG 
monitoring 
3) Repeat 
Neuroimaging 
4) Add/change AEDs 
5) Epilepsy surgery 
RECURRENT SEIZURES: 
Check for: 
1) Appropriate drug 
2) Drug dose 
3) Drug compliance 
4) Drug interaction 
5) Any metabolic disorder 
6) Any structural lesion 
7) Degenerative disease 
8) Intractable seizures 
SUSPECTED SEIZURE EPISODE 
RULE OUT SEIZURE MIMICS 
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COMMON ANTICONVULSANTS AND THEIR DOSAGES:[1] [4] 
ANTIEPILEPTIC 
DRUG 
FDA 
APPROVED 
INDICATIONS 
MAINTENANCE 
DOSAGE 
(mg/kg/day) 
DOSING 
INTERVAL 
THEREPEUTIC 
LEVELS 
1.Carbamazepine Partial and GTCS 10-20 tid or qid 3-12 mg/L 
2.Clobazam LGS 10-20mg/day bid or tid 60-200 ug/L 
3.Clonazepam 
Absence, 
myoclonic 
seizures, LGS 
0.05-0.2 bid or tid 25-85 ug/L 
4.Diazepam Partial seizures 0.01-0.25 IV bid or tid 100-700 ug/L 
5.Ethosuximide Absence seizures 20-30 bid or tid 40-100 mg/L 
6.Gabapentin Partial seizures 30-60 Tid 2-20 mg/L 
7.Lacosamide Partial seizures 4-12 bid <15 ug/L 
8.Lamotrigine LGS, partial and GTCS 5-15 bid or tid 1-15 mg/L 
9.Levitiracetam Myoclonic, partial and GTCS 20-40 bid or tid 6-20 mg/L 
10.Lorazepam Status epilepticus 0.05-0.1 bid or tid 20-30 ug/L 
11.Oxcarbazepine Partial seizures 20-40 bid 13-28 mg/L 
12.Phenobarbitone 
Myoclonic, 
partial, GTCS, 
and status 
3-5 bid or qid 10-40 mg/L 
13.Phenytoin Partial,GTCS&status 4-7 bid or tid 5-20 mg/L 
14.Primidone Partial & GTCS 10-20 bid or tid 4-13 mg/L 
15.Topiramate LGS, partial, GTCS 3-9 bid or tid 2-25 mg/L 
16.Valproate 
Absence, 
Myoclonic, 
partial & GTCS 
15-40 bid or tid 50-100mg/L 
17.Vigabatrin Infantile spasms & partial seizures 50-150 bid 20-160 ug/mL 
28.Zonisamide Partial seizures 4-8 bid or qid 10-40 mg/L 
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Side effects of common anticonvulsants: [1] [4] 
ANTI-EPILEPTIC DRUGS SIDE EFFECTS: 
1.Benzodiazepines  Drowsiness/sedation 
 Hyperactivity 
 Drooling/increased secretions 
 Apnea 
2. Carbamazepine  Leukopenia 
  Weight gain 
 Hyponatremia 
 Steven-Johnson syndrome  
 Agranulocytosis 
 Aplastic anemia 
 Hepatotoxic 
3.Gabapentin  Aggression/Hyperactivity 
4.Lacosamide  Diplopia 
 Headache/dizziness 
 Cardiac arrhythmias 
5.Lamotrigine  Headache/dizziness 
 Ataxia 
 Steven-Johnson syndrome 
6.Levitiracetam  Behavioural symptoms 
7.Oxcarbazepine  Headache/dizziness 
 Rash 
 Hypertrichosis 
 Gingival hypertrophy 
 Hyponatremia 
8.Phenobarbitone  Hyperactivity/distractability 
 Mood fluctuations 
 Hepatotoxic 
 Steven-Johnson syndrome 
9.Phenytoin  Gingival hypertrophy 
 Hirsuitism 
 Nystagmus/ataxia 
 Steven-Johnson syndrome 
 Hepatotoxic 
10.Primidone  CNS toxicity 
 Hepatotoxic 
 Steven-Johnson syndrome 
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11.Topiramate  Cognitive dysfunction 
 Renal calculi 
 Glaucoma 
 
12.Valproate 
 Weight gain 
 Hyperammonemia 
 Alopecia 
 Hepatic & pancreatic toxicity 
13.Vigabatrin  Hyperactivity 
 Retinopathy/ Visual field defects 
14.Zonisamide  Fatigue/dizziness 
 Psychomotor slowing 
 Ataxia 
 
DRUGS OF CHOICE: 
TYPE OF SEIZURE DRUGS OF CHOICE 
1.Neonatal seizure Phenobarbitone 
2.Cerebral palsy with epilepsy Valproate,Levitiracetam ( add on 
clobazam) 
3.Infantile spasms Prednisolone(or ACTH), Vigabatrin 
4.Benign Rolandic epilepsy None or Valproate, clobazam 
5.Juvenile absence epilepsy Valproate 
6.Idiopathic Generalised 
Epilepsy(IGE)/ Juvenile 
Myoclonic Epilepsy(JME)-boys 
Valproate, Levitiracetam, Lamotrigine 
7. Idiopathic Generalised 
Epilepsy(IGE)/ Juvenile 
Myoclonic Epilepsy(JME)-girls 
Levitiracetam, Lamotrigine 
8.Focal epilepsy Oxcarbazepine/carbamazepine, 
Levitiracetam, Phenytoin 
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OTHER TREATMENT MODALITIES:[1] [4] 
KETOGENIC DIET: 
 Those seizures that have failed to respond to the above antiepileptic 
drugs can be treated with ketogenic diet, which is found to be 
effective to some extent in the management of  refractory 
tonic/atonic/myoclonic/atypical absence seizures and uncontrolled 
infantile spasms and Lennox-Gastaut syndrome. 
 Initially, during the hospital stay, starvation is instituted until 
ketosis occurs. The child may go in for hypoglycaemia, hence blood 
sugars are to be monitored. The diet should contain 3 to 4 parts of 
fat added to 1 part of carbohydrate. Protein is later introduced with 
supplementation of vitamins and minerals. 
 Vomiting , dehydration , sepsis and metabolic abnormalities like 
acidosis, hypoproteinemia, elevation of  cholesterol/triglycerides, 
liver and pancreatic enzymes may occur. QT prolongation can occur 
and hence ECG monitoring is necessary 
STEROIDS: 
ACTH or Prednisolone (at a dose of 2mg/kg/day) because of their anti-
inflammatory action are used in the management of : 
 West syndrome 
 Lennox-Gastaut syndrome 
 Landau-Kleffner syndrome 
 Myoclonic astatic epilepsy 
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They are usually given for a period of 2-3 months followed by 
tapering, but relapses are common during tapering. In such cases, therapy 
may be needed for 1 year. 
IVIG: 
It is found to effective in: 
 West syndrome 
 Lennox-Gastaut syndrome 
 Landau-Kleffner syndrome 
due to its anti-inflammatory action. The usual dosing is 2g/kg given over 4 
days followed by 1g/kg once a month for 6 months. 
 
EPILEPSY SURGERY: 
Epilepsy surgeries have to be considered in patients whose seizures 
have failed to get controlled with 3 drugs, as the chance of being seizure 
free by AEDs falls below <10%. If surgeries performed at an earlier age, 
the function of that area(epileptogenic zone) are transferred to the nearby 
area. They are generally reserved for refractory seizures caused by: 
 Cortical dysplasia 
 Landau-Kleffner syndrome 
 Hypothalamic hamartoma 
 Tuberous sclerosis 
 Sturge-Weber syndrome 
 Rasmussen encephalitis 
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The procedures that are usually done are: 
 Focal resection of the epileptogenic zone 
 Hemispherectomy 
 Multiple subpial transection 
 Corpus callosotomy 
 Vagal nerve stimulation 
 
DISCONTINUATION OF DRUG THERAPY:[4] 
This should be attempted only when the child is seizure free for 2 
years and it is a benign epilepsy syndrome. Severe epilepsy syndromes may 
require a longer duration of therapy. The following factors are associated 
with higher frequency of relapse of seizures following discontinuation: 
 Older age of onset 
 Multiple seizure types 
 Longer duration of seizures 
 Child on more than 1 AED 
 Abnormal EEG 
The drugs should be tapered slowly over a period of 3-6 months. 
Abrupt withdrawal of the drug is associated with withdrawal seizures. 
Intranasal midazolam or rectal diazepam are prescribed for emergency use 
when the drugs are being withdrawn. 
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NEUROBEHAVIORAL COMORBIDITIES IN CHILDREN WITH 
EPILEPSY:[7] 
The effects of epilepsy are as serious as the disorder itself. Among 
them, the important consequences are cognitive impairment and behaviour 
changes. Cognitive function includes the capacity of brain to solve 
problems/ memorise information/ focus attention and maintaining adaptive 
behaviour. Problems with Memory, mental slowing and inattention are the 
most common cognitive problems, resulting in poor school work in children 
Studies have shown that most children with epilepsy have associated 
comorbidities. 
Among them the most common ones are: 
o Autistic Spectrum Disorder (ASD) 
o Attention Deficit Hyperactivity Disorder (ADHD) 
o Developmental Coordination Disorder (DCD) 
o Emotional disorders, such as depression and anxiety 
 
These conditions can further affect the learning and behaviour of the 
child and make the management of epilepsy a difficult process. Hence 
appropriate management of them is also mandatory. 
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The behavioural and cognitive effects of epilepsy depends on the 
following factors : 
 Aetiology of the seizures: 
If the cause of seizures involves any underlying damage to 
brain, then it is related to cognitive dysfunction as well. In cortical 
dysplasia, abnormality is found in the cerebral Cortex and the 
degree of the intellectual impairment depends on the extent of the 
underlying malformation. 
 Type of seizure: 
The type of seizure is also related to the degree of cognitive 
impairment. Generalised tonic–clonic seizures are found to be 
associated with more cognitive impairment than absence seizures 
and focal seizures. The risk is highest if the child presented with 
status epilepticus and has multiple seizure types. 
 Nature of epilepsy syndrome  
o Idiopathic generalised epilepsies include benign myoclonic 
epilepsy of infancy, childhood absence epilepsy(CAE), juvenile 
absence epilepsy, juvenile myoclonic epilepsy(JME). JME, being 
the most common is associated with frontal lobe dysfunction, in 
which there is impairment of the executive functions like concept 
formation, mental flexibility, abstract reasoning, cognitive speed 
and planning. 
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o Idiopathic partial epilepsies include Benign childhood epilepsy 
with centrotemporal spikes (benign Rolandic epilepsy), in which 
the epilepsy is usually outgrown by children in their mid to late 
teens, though sometimes it is associated with deficits in 
reading/writing, auditory–verbal learning, visual perception, 
memory, fine motor, executive functions and attention  
o Acquired epileptic aphasia ((Landau–Kleffner syndrome) is 
associated with language impairment,because of damage to 
auditory–verbal system. 
o Lennox–Gastaut syndrome is associated with by intellectual 
disability and behavioural problems 
 Location of the epileptogenic focus: 
o  Verbal functions are affected in left-hemisphere seizures.  
o Visual memory and constructional disabilities are affected in 
right-hemisphere seizures 
o Temporal lobe epilepsy: Deficits in verbal memory is seen in left-
temporal lobe epilepsy and deficits in visual memory in right-
temporal lobe epilepsy. 
o Frontal lobe epilepsy: Deficits are seen in motor skills, attention, 
working memory, response inhibition, planning and psychomotor 
speed 
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 Seizure frequency: 
o Increase in the seizure frequency is associated with an increase in 
the intellectual impairment. 
 Duration of illness: 
o Refractory temporal lobe epilepsy that persists for longer 
duration is associated with poor intellectual functioning.  
 Age at onset: 
o Studies have shown that the younger the age of onset of seizure, 
the higher will be the adverse effect on the IQ. 
 Effect of Anti-epileptic drugs: 
o Anti-epileptic drugs cause a decrease in the neuronal excitability 
thereby affecting the cognitive functioning.  
o  Psychomotor speed, memory, language and mood are generally 
affected.  
o Polytherapy has been found to be associated with more adverse 
effects than monotherapy. 
o Those drugs that act on sodium channels have the least cognitive 
side-effects, whereas those with the GABAergic action have the 
most. 
o Older drugs like phenobarbitone, phenytoin, carbamazepine and 
valproate cause psychomotor slowing. 
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o Newer drugs like lamotrigine and oxcarbazepine (sodium channel 
blockers) may have a positive effect on learning and psychomotor 
speed. 
Aggressive seizure control, choosing anti-epileptic drugs with good 
cognitive profiles, and appropriate treatment of comorbid conditions are 
necessary for the prevention of cognitive and behavioural disturbances in 
children with epilepsy. 
In our study, we use various questionnaires to screen for the 
presence of associated Neurobehavioral comorbidities in children with 
seizure disorder and confirmation will be performed by child 
psychiatrist 
The questionnaires that will be used are: 
 Strength & difficulties questionnaire 
 Quality of life in childhood epilepsy questionnaire 
 Child behaviour checklist questionnaire 
 Developmental Coordination  disorder questionnaire 
These questionnaires have got separate scoring systems and the data 
collected will be entered in an excel sheet. The sample questionnaires are 
attached in the annexures. Apart from these, a separate questionnaire is also 
used for obtaining the data about the seizure episodes. 
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REVIEW OF LITERATURE 
1. Modage Anita et al[8] in her  case control study on  children with 
epilepsy (CWE) aged 5-12 years and their matched controls, applying 
Strength and Difficulties Questionnaire (SDQ), analysed  and  
concluded that emotional symptoms, conduct problems, Hyperactivity  
& peer relationship problems were commoner in the cases than 
controls.  The overall prevalence of behavioural comorbidities in 
epileptics was 39.1% as compared to 7.9% in non epileptics. Authors 
concluded that neurobehavioral comorbidities are significant in 
children with epilepsy and need to be addressed with appropriate 
interventions. 
2. Kind et al[9] in his longitudinal study on epileptic children, analysed 
and concluded that the prevalence of lifetime epilepsy was 20.9 per 
1,000 .Neurobehavioral comorbidities were very common in children 
with lifetime epilepsy compared to controls – the common conditions 
being ADHD, ASD and cognitive impairments, emphasising the need 
for incorporation of  a comprehensive management plan for them. 
3. Kari ModalsliAaberg et al[10] In her study on 6635 epileptic children out 
of 1,125,161 recruited, 80% of children with epilepsy had ≥1 comorbid 
disorder. Concurrent medical disorders (Gastrointestinal 
disorders/musculoskeletal disorders/chronic lower respiratory disorders 
etc.), neurologic disorders (cerebral palsy/ headache/ congenital 
neurologic malformations etc.) and developmental/psychiatric disorders 
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(Autism/ ID/ ADHD etc.) were commoner in epileptics compared to the 
children without epilepsy, stressing the need for addressing the 
comorbid diseases in this group. This study is in line with our study, 
though our sample population is comparatively much smaller. 
4. Ike OluwaAbiolaLagunju et al[11] conducted a study in which 40 
children with newly diagnosed epilepsy (24 males and 16 females) in 
the age group of  6-16 years were assessed for Intelligence quotient 
(IQ) using the Wechsler Intelligence Scale for Children-Fourth Edition 
(WISC-IV).On analysis, the mean IQ was in the normal range (FSIQ 
scores <85) for 52.5% (n = 21) of the participants and the rest (47.5%) 
had a score between the borderline and severe category for intellectual 
disability. Given the high prevalence of significant cognitive 
dysfunction, authors concluded that all children with epilepsy should 
have routine IQ assessment for early intervention  and improved 
outcomes. This is comparable with our study, which has brought out a 
difference in IQ among the cases and controls, quantitatively.  
5. Halma E et al[12] published a systematic review in which 13 Studies that 
included epileptic children from one month to 18 years of age and on 
levetiracetam, (plus other AEDs on a stable regimen) for at least two 
months were analyzed. Out of 727 patients using levetiracetam 
(finalized from3 RCTs), a total of 62 behavioural side-effects were 
noted in 203 patients. These effects led to discontinuation of 
levetiracetam in only two of 102 patients (2.0%). Hostility, nervousness 
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and aggression were reported most commonly. Authors concluded that 
children using levetiracetam have a risk of developing several 
behavioral side-effects (significant relative risk of 2.18). 
6. Guilfoyle SM et al [13]  conducted a retrospective study  in which 
baseline psychological functioning  of children(age = 2-11 years)  and 
adolescents(age = 12-18 years)  with new onset epilepsy were assessed 
using Behavior Assessment System for Children. The behavioral side 
effects following 1 month of AED therapy was assessed using Pediatric 
Epilepsy Side Effects Questionnaire. After analysis, authors concluded 
that children had significantly greater AED behavioral side effects 
(M = 25.08 ± 26.36) compared to adolescents (M = 12.36 ± 17.73). 
Also Higher hyperactivity / impulsivity at baseline significantly 
predicted higher AED behavioral side effects 1 month after AED 
initiation in both age groups. Sodium valproate and levetiracetam had 
significantly greater behavioural side effects compared to other AEDs. 
7. Amir A. Sarhanet al[14] conducted a cross-sectional study in which 
50epileptic children who were maintained on antiepileptic medications 
were administered Wechsler Intelligence Scale (IQ), Child Behaviour 
Checklist, and Developmental Profile-3 scale. On analysis, it was found 
that children with earlier onset, increased frequency of seizures, 
prolonged duration of epilepsy,  those with generalized epilepsy &on  
polytherapy performed worse  on all scales. Authors concluded that 
childhood epilepsy is associated with significant cognitive deficits, 
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intellectual decline, and behavioural problems, and are influenced by 
multiple factors. This study concurs with the inference of our study. 
8. Dazhi Cheng et al[15] in his study on 37 childhood absence epilepsy 
[CAE] patients (divided into drug naive group and treated group) and 
37 age- and gender-matched healthy control subjects using a 
computerized neuropsychological battery test  for cognitive dysfunction  
concluded  that neurocognitive dysfunction was more prevalent in CAE 
patients compared to the controls. The drug-naive subgroup had 
cognitive deficits in reasoning, visual attention, and executive function 
[typical functions of the frontal lobe]. Treated subgroup had cognitive 
deficits only in visual attention. No significant differences between 
groups were found for other cognitive tests. Authors concluded that 
CAE patients are more prone for frontal lobe dysfunction. 
9. Ahyuda et al[16] in his retrospective study on co morbidities and risk 
factors associated with newly diagnosed epilepsy (7654 out of  6 
million children) showed that neurobehavioral comorbidities were more 
prevalent in children with epilepsy  than without epilepsy (60%, 99% 
CI = 58.1–61.0 vs. 23%, CI = 23.1–23.2). Also, epileptic children were 
more likely to have multiple comorbidities than those without epilepsy. 
Putative risk factors for epilepsy were detected in 28% of children with 
epilepsy. Those with both epilepsy and risk factors were more likely to 
have intellectual disabilities. Authors concluded that screening for 
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associated risk factors and neurobehavioral comorbidities should be 
mandatory in all children with epilepsy to have a better outcome. 
10. Dave F. Clarke et al[17] in his prevalence study on Autism spectrum 
disorder in children attending a tertiary care epilepsy clinic using 
validated autism screening questionnaires (ASQ), found that 
approximately 32% of epileptic children fit the ASQ criteria for having 
ASD, most of whom were not previously diagnosed. Seizures also 
occurred earlier (approximately 2 years) in children who are at risk of 
having ASD. Authors concluded that children with epilepsy are at 
greater risk of having ASD (although confirmatory diagnostic 
evaluations are further needed) and so, their early diagnosis and 
intervention may improve the outcome. 
11. Reilly C et al[18] conducted a prospective population based study on 
neurobehavioral comorbidities in children with active epilepsy aged 5-
15 years. Out of 85 children who were enrolled into the study, 80% of 
children with active epilepsy had a DSM-IV-TR behavioural disorder 
and/or cognitive impairment (IQ<85). Intellectual disability (ID) 
(40%), attention-deficit/hyperactivity disorder (ADHD) (33%), and 
autism spectrum disorder (ASD) (21%) were the most common 
neurobehavioral comorbidities. Those who had seizures in the first 24 
months compared with first seizures at 24 to 60 months or 61+ months  
and  those on polytherapy were independently associated with ID and 
the presence of ID was more commonly associated with a diagnosis of 
29 
 
ASD. It was concluded that screening for 
neurobehavioral comorbidities should be an integral part of 
management in children with active epilepsy. 
12. Claudia L. Kernan et al[19] in her comparative study of neurobehavioral 
profile of children with CPS, CAE and normal controls, concluded that 
the neurocognitive functioning of children with epilepsy was poorer 
than the controls in all domains of cognition. Of the two epileptic 
groups, children with CPS showed poorer performance than the CAE 
group in IQ assessment, whereas the executive functioning, verbal and 
visual memories were comparable between the two. The study 
highlights the importance of neuropsychological screening to identify 
subtle cognitive deficits in epileptic children. 
13. Bektas G et al[20] conducted a prospective case control study on 
children aged 6 to 16years diagnosed with new-onset focal seizures and 
on treatment with either levetiracetam or sodium valproate. 
Psychosocial and behavioural functioning were assessed using 
Strengths and Difficulties Questionnaire (SDQ) and Children's 
Depression Inventory (CDI) at baseline, 1 and 3-months follow-up. Out 
of 101 children, 32 were on levetiracetam therapy, 19 were on valproic 
acid therapy and 50 were healthy controls .No statistically significant 
difference was observed in CDI & SDQ scores between patients and 
healthy subjects as well as those on levetiracetam or valproic acid  
(p>0.05). Thus, psychosocial and behavioural side-effects of 
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levetiracetam are not common at lower doses. Also, no significant 
difference was found between the valproic acid and levetiracetam 
treatment groups. 
14. Chen B et al[21] conducted a study on the psychiatric and behavioural 
side effect (PBSE) profiles of antiepileptic drugs (AEDs) in children 
and adolescent patients with epilepsy. It was found that PBSEs and 
IPBSEs (PBSEs associated with Intolerability) occurred in 13.8% and 
11.2% of patients, respectively. After analysis, authors concluded that 
those children who had a history of psychiatric condition, absence 
seizures, intractable epilepsy, or frontal lobe epilepsy are more likely to 
develop PBSE. These PBSEs (16.2%) and PBSEs associated with 
Intolerability (13.4%) appear to occur more frequently in patients 
taking Levetiracetam compared to other AEDs 
15. Om P Mishra et al[22] conducted a case control study in which children 
with epilepsy were compared with unaffected controls (140 cases and 
157 controls). Child Behaviour Checklist (CBCL) was used to assess 
the behaviour problems. On analysis it was found that the mean CBCL 
scores were significantly higher in cases than the controls, indicating 
the presence of clinically significant abnormal behaviour in epilepsy 
group. Also, it was found that the following factors have significant 
correlation with behavioural problems in both the age groups - younger 
age of onset, frequency of seizures, duration of disease and 
polytherapy. 
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16. Tanabe T et al[23] conducted a cross sectional study applying the 
strengths and difficulties questionnaire (SDQ) in 83 epileptic children 
in the age group of 4 to 16 years to screen for behavioural problems. 
On analysis it was found that the scores of the subscales 
‘Hyperactivity’ (p<0.0001), 'peer problems'(p<0.0001) and 'conduct 
problems' (p<0.01), were above the normal range in significant 
numbers of children. Also, these poor SDQ scores correlated with early 
age of onset of seizures. Thus, authors concluded that SDQ scores can 
be used to diagnose behavioural problems in children with epilepsy and 
these comorbidities should be addressed as early as possible for a better 
quality of life in such children. 
17. NageshAdla et al[24] conducted a prospective observational study in 
which 104 children aged 4-13 years with epilepsy were recruited to 
assess the quality of life using QOLCE questionnaire. On analysis it 
was found that the mean overall QOL score was 46.82 ± 10.90 and was 
affected by the type of epilepsy, frequency of seizures, antiepileptic 
drugs and maternal education. Cognitive dysfunction and social 
impairment were found to be affected more severely. Authors 
concluded that the quality of life is weaker in children with epilepsy 
and the associated cognitive and social impairment need to be 
addressed. 
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18. Michael Freilinger et al[25] conducted a study in which 108 children 
aged 5 to 18 years with various epilepsy syndromes were recruited and 
CBCL questionnaire was administered to assess the prevalence of 
behavioural and emotional problems. On analysis,  it was found that 
22.2% of the study population showed behavioural or emotional 
problems of the moderate to severe type as measured by the CBCL total 
scores. It was found that higher CBCL scores were associated with 
those children who had an early age of onset and were on polytherapy. 
Therefore, the authors concluded that these psychosocial issues need to 
be addressed along with the treatment of epilepsy. 
19. JayashreeNadkarni et al[26] conducted a cross-sectional study to identify 
the association of demographic and epilepsy variables with the QOL in 
children with epilepsy.102 children with epilepsy aged between 4 and 
15 years were chosen and administered QOLCE questionnaire. The 
mean age of the study group was 8.75 ± 3.6 years, comprised of 61 
boys and 41 girls. On analysis it was found that the overall QOL was 
affected more in children living in rural areas with lower 
socioeconomic status and belonging to older age group. With regard to 
disease characteristics, a poorer QOL was observed in children with 
increased seizure frequency, in those receiving polytherapy and on 
longer duration of treatment. Authors concluded that it is necessary to 
measure QOL in children with epilepsy apart from seizure control and 
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to initiate interventions to address the behavioural and emotional 
problems 
20. Stuart D. W. Smith et al[27] conducted a study to detect the symptoms of 
Developmental Coordination Disorder (DCD) in children with 
Rolandic epilepsy, their siblings and normal controls. 18 children with 
rolandic epilepsy, 9 of their siblings, 17 controls all belonging to age 
group of 7-17 years with IQ>80 were administered Developmental 
Coordination Disorder Questionnaire (DCDQ). On analysis, it was 
found that 44% of children with RE came under the category of 
suspected DCD group, which was larger than the controls (χ²=4.58, p= 
.032) and siblings (χ²=3, p= .08). Therefore, it was concluded that the 
prevalence of symptoms of DCD was higher in children with RE 
compared to controls and siblings. 
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STUDY JUSTIFICATION 
 The prevalence of neurobehavioral comorbidities in children with 
seizure disorder is on the higher side and these add significant 
burden as well as pose difficulty in treatment of the condition. 
 Previous studies have shown that these comorbidities are usually 
under recognized and the interventions done to treat/ manage them 
have shown a good response. 
 Most of the evidence of these comorbidities are obtained from 
studies done in developed countries and there is only limited data 
from developing countries. 
 Therefore, screening of all children with seizure disorder for 
cognitive & behavioural difficulties is mandatory and it should be 
an integral part of management in childhood seizures. 
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OBJECTIVES 
 
PRIMARY OBJECTIVE –  
 To compare the clinical & neurobehavioral profile of children with  
seizure disorder  versus healthy controls in a tertiary health care 
centre 
 
SECONDARY OBJECTIVE –  
 To compare the effect of single AED & multiple AEDs on the 
neurobehavioral outcome of children with seizures 
 To co-relate the Sociodemographic characteristics with the epilepsy 
pattern in such children 
 To describe the prevalence & pattern of behavioural problems in 
children with recent onset seizures & long standing seizure disorder 
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METHODOLOGY 
 STUDY DESIGN- Case Control Study 
 STUDY SETTING- Institute Of Child Health and Hospital For 
Children Egmore 
 STUDY PERIOD –August 2017 to August 2018. 
 STUDY POPULATION-  
Inclusion criteria- 
All children between 6-12 years of age diagnosed to have seizure 
disorder 
 on single AED(seizure free for 6months) 
 on multiple AEDs 
 Age& sex matched healthy controls 
Exclusion criteria- 
 Children with Developmental Delay(all domains) 
 Children with known neurological disorders 
 children with known psychiatric illness 
 Medical illness associated with behavioural abnormality 
 SAMPLE SIZE: All children between 6-12 years of age diagnosed 
to have seizure disorder 
 on single AED(seizure free for 6months)-50 
 on multiple AEDs-50 
 Age & sex matched healthy controls-100. 
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CASE DEFINITIONS: 
SEIZURE: 
 A seizure is a sudden change in behaviour caused by electrical 
hypersynchronization of neuronal networks in the cerebral cortex. [2] 
 
EPILEPSY: 
 Epilepsy can be defined as: (when any of the following exist): [2] 
 At least 2 unprovoked (or reflex) seizures occurring greater than 24 
hours apart. 
 1 unprovoked (or reflex) seizure and a probability of further seizures 
similar to the general recurrence risk after two unprovoked seizures 
(e.g.≥60%) occurring over the next 10 years. Examples: remote 
structural lesions such as stroke, CNS infection, or traumatic brain 
injury. 
 Diagnosis of an epilepsy syndrome. 
The second criterion emphasizes the use of neuroimaging and EEG 
in the evaluation of patients with a first-time seizure (added by the ILAE 
working group in 2014) 
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STUDY MANOEUVRE: 
All children between 6-12 years of age fulfilling the inclusion criteria: 
Diagnosed to have seizure disorder 
1) on single AED(seizure free for 6months) 
2) on multiple AEDs& 
3) Age & sex matched healthy controls 
 
Will be screened for associated Neurobehavioral comorbidities 
using various questionnaires after obtaining informed consent from 
parent/guardian and confirmation will be performed by child 
psychiatrist. 
 
The questionnaires that will be used are: 
 Strength & difficulties questionnaire 
 Quality of life in childhood epilepsy questionnaire 
 Child behaviour checklist questionnaire 
 Developmental Coordination  disorder questionnaire 
These questionnaires have got separate scoring systems and the data 
collected will be entered in an excel sheet. The sample questionnaires are 
attached in the annexures. 
STRENGTH & DIFFICULTIES QUESTIONNAIRE: 
It contains 25 items totally placed as 5 items each in 5 scales and the 
parent version is administered. The scales are: 
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 Emotional problems scale 
 Conduct problems Scale 
 Hyperactivity scale 
 Peer problems scale 
 Prosocial scale 
The scoring components are: 
 Somewhat True 
 Not True  
 Certainly True  
‘Somewhat True’ is scored as 1 always. ‘Not True’ and ‘Certainly 
True’ varies in each scale (zero or 2). For each of the 5 scales the score will 
range from 0 to 10. 
Total difficulties score is calculated by summing up scores from 4 
scales (Emotional problems scale + Conduct problems Scale+ Hyperactivity 
scale+ Peer problems scale). Pro-social scale is not taken into account. The 
score ranges from 0 to 40.A total difficulties score of : 
o 0-13 was normal 
o  14-16 was borderline 
o  17-40 was abnormal 
 Externalising scores: The externalising score is the sum of the 
conduct and hyperactivity scales, and it ranges from 0 to 20. 
 Internalising score is the sum of the emotional and peer problems 
scales and ranges from 0 to 20. 
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QUALITY OF LIFE IN CHILDHOOD EPILEPSY  
QUESTIONNAIRE: 
The following sub-scales are included under this questionnaire: 
1. Cognitive functioning (includes 22 items) 
2. Emotional functioning (includes 17 items) 
3. Social functioning (includes 7 items) 
4. Physical functioning (includes 9 items) 
The Scoring is done as follows:  
1. All items are recoded so that higher scores will indicate higher well-
being.  
2. These pre-coded numeric values are converted to a 0-100 point scale and 
responses are coded as 0, 25, 50, 75, 100. Higher scores will reflect a better 
quality of life.  
3. The mean value of the items in each subscale is calculated. 
4. The un-weighted mean of the four subscales is used to calculate the total 
score.  
CHILD BEHAVIOUR CHECKLIST QUESTIONNAIRE: 
 This checklist contains multiple items that describe the child and is 
scored as follows: 
 0 -Not True 
 1 - Somewhat or Sometimes True 
 2 –Very True or often True 
 Age 6-11 years: 
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 Cumulative score of:  <38 – NORMAL 
    39-48 – BORDERLINE 
    >49 – CLINICALLY SIGNIFICANT 
  
Age 12-18years: 
 Cumulative score of:  <39 – NORMAL 
    40-51 – BORDERLINE 
    >52 – CLINICALLY SIGNIFICANT 
DEVELOPMENTAL COORDINATION DISORDER 
QUESTIONNAIRE: 
 There are 15 items in this questionnaire which are grouped under the 
following sub scales: 
 Control during movement ( includes 6 items) 
 Fine motor/ Handwriting (includes 4 items) 
 General coordination (includes 5 items) 
Each item is given a score ranging from 1 to 5 (1 being the lowest and 5 
being the highest). The maximum total score is 75 
Children Aged 5 years 0 months to 7 years 11 months  
SCORE OF: 15-46 indication of DCD or suspect DCD  
          47-75 probably not DCD  
Children Aged 8 years 0 months to 9 years 11 months  
SCORE OF: 15-55 indication of DCD or suspect DCD  
         56-75 probably not DCD  
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Children Aged 10 years 0 months to 15 years  
SCORE OF: 15-57 indication of DCD or suspect DCD  
         58-75 probably not DCD 
Apart from these, a separate questionnaire is also used for obtaining 
the data about the seizure episodes. 
 
STATISTICAL ANALYSIS: 
 The data will be coded and entered in excel sheet. 
 The study subjects namely seizure disorder and normal children 
were compared in respect of their clinical and neurobehavioral 
profile of continuous variables by student independent “t” test.  
 The categorical variables were compared by χ2 (Chi-square) test. 
 Within the Seizure disorder group, those on monotherapy and 
polytherapy were compared by student independent “t” and χ2 
(Chi-square) test according to the type of variables.  
 The P - values less than or equal to 0.05 (P≤0.05) were treated as 
statistically significant. 
 
ETHICAL CONSIDERATION:  
 The study was commenced after the ethical committee clearance.  
 This study does not include any experimentation.  
 Patients will be informed of the procedure done and consent will be 
obtained. 
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 Strict confidentiality will be maintained while analysing and 
presenting the data. 
 No one will be receiving any benefit personal or professional from a 
commercial party directly or indirectly to the subject of this study. 
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OBSERVATION AND RESULTS 
Results:  
Description and homogeneity: 
 The children with seizures (cases) and normal children (control) 
were described according to their demographic profiles such as age and 
gender. 
Table-1: Age wise distribution of cases & controls: 
Age group 
(years) 
CASES CONTROLS 
Frequencies % Frequencies % 
6-9 57 57.0 57 57.0 
10-12 43 43.0 43 43.0 
Total 100 100.0 100 100.0 
Mean ±SD 9.2±1.7 9.2±1.7 
 
 The table-1 shows the age wise distribution of cases & controls. The 
mean ages of both groups were 9.2±1.7 years. 
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Table-2: Gender wise distribution of cases & controls: 
Gender 
CASES CONTROLS Total 
No % No % No % 
Males 51 51.0 51 51.0 102 51.0 
Females 49 49.0 49 49.0 98 49.0 
Total 100.0 100.0 100.0 100.0 200 100.0 
 
 The table-2 shows the Gender wise distribution of cases & controls. 
The male and females were 51% and 49% in both groups.  
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Table-3: Age and gender wise distribution of cases & controls: 
Age group 
(years) 
CASES CONTROLS 
Male Female Male Female 
No % No % No % No % 
6-9 34 66.7 23 46.9 34 66.7 23 46.9 
10-12 17 33.3 26 53.1 17 33.3 17 53.1 
Total 51 100.0 49 100.0 51 100.0 49 100.0 
Mean 
±SD 8.8±1.7 9.5±1.8 8.8±1.7 9.5±1.8 
  
 
The table-3 shows the age and gender wise distribution of cases & 
controls. The mean ages of males and females were 8.8±1.7 years and 
9.5±1.8 years. 
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Comparison of results of questionnaires between cases and controls:  
 The two groups were administered the questionnaires mentioned in 
the study manoeuvre [Developmental Coordination Disorder Questionnaire 
(DCDQ), Quality of Life in Childhood Epilepsy (QOLCE), Child behaviour 
check list (CBCL) and strength and difficulty Questionnaire (SDQ). 
 
Comparison of results of DCD Questionnaire between the two 
groups according to  their ages: 
 The following chart shows the scores of DCDQ between the two 
groups. The mean DCD score of seizure group was 72.9±4.9. The mean 
DCD score of control group was 74.8±1.2. The difference between the 
means was statistically very highly significant (P<0.001). 
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CASES CONTROLS
MEAN 55.4 84.3
SD 30.7 13.5
QOLCE SCORES 
Table-4: Comparison of results of Quality of Life in Childhood Epilepsy 
(QOLCE) questionnaire between the two groups: 
 
Variable 
Seizure 
group 
Control 
group Difference 
b/w means “t” df Sig 
Mean SD Mean SD 
QOLCE 55.4 30.7 84.3 13.5 28.9 8.620 198 P<0.001 
 
 The above table - 4 compares the scores of QOLCE questionnaire 
between the seizure and control groups. The mean QOLCE score of seizure 
group was 55.4±30.7 and the same of the control group was 84.3±13.5. The 
difference between the means of the two groups was statistically very 
highly significant (P<0.001). 
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Table-5: Comparison of results of Child behaviour check list (CBCL) 
questionnaire between Seizure and control groups: 
Variable 
Seizure 
group 
Control 
group Difference 
b/w means “t” df Sig 
Mean SD Mean SD 
CBCL 38.6 40.6 5.4 20.6 33.2 7.297 198 P<0.001 
 
 The CBCL scores of seizure and control groups were compared in 
the above table-5. The mean CBCL score of seizure group was 38.6±40.6. 
The mean CBCL score of control group was 5.4±20.6. The difference of 
means between the two groups was statistically very highly significant 
(P<0.01). 
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Table-6: Comparison of raw scores of CBCL questionnaire between the 
seizure and control groups in the age group of 6-11 years: 
 
Groups CBCL Score Category No % Z Sig 
Seizures 
<38 Normal 44 50.6 
7.072 
 P<0.001 
39-48 Border line 0 0.0 
49+ Clinically. Significant 43 49.4 
Total 87 100.0 
control 
<38 Normal 81 93.1 
39-48 Border line 0 0.0 
49+ Clinically. Significant 6 6.9 
Total 87 100.0 
  
Table-6 states the comparison between seizure and control groups in 
terms of raw CBCL scores (Age: 6-11 years). In the seizure group, 50.6% 
had CBCL scores <38 and 49.4% had scores >49. In the control group, 
93.1% had CBCL scores <38 and 6.9% had scores >49. The differences 
between the two groups were statistically very highly significant (P<0.001).   
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Table-7: Comparison of raw scores of CBCL questionnaire between the 
seizure and control groups in the age group of 12-18 years: 
 
Groups CBCL Score Category No % Z Sig 
Seizures 
<39 Normal 10 76.9 
1.976 P<0.05 
40-51 Border line 0 0.0 
52+ Clinically. Significant 3 23.1 
Total 13 100.0 
Control 
<39 Normal 13 100.0 
40-51 Border line 0 0.0 
52+ Clinically. Significant 0 0.0 
Total 13 100.0 
 
 Table-7 states the comparison between the seizure and control 
groups in terms of raw CBCL scores (Age: 12-18 years). In the seizure 
group, 76.9% had CBCL scores <39 and 23.1% had scores >52. In the 
control group, all children had CBCL scores <39 (100%). The differences 
between the two groups were statistically very highly significant (P<0.05).   
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Table-8:Comparison of results of Strength and Difficulty (SD) 
questionnaire with its components between Seizure and control groups: 
 
S&D Components 
Seizure Control Difference 
b/w means 
“t” df Sig 
Mean SD Mean SD 
Emotional 1.3 1.6 0.2 0.9 1.1 5.609 198 P<0.001 
Conduct 3.9 3.9 0.5 1.9 3.4 7.745 198 P<0.001 
Hyper activity 4.8 4.8 0.6 2.2 4.2 8.088 198 P<0.001 
Peer problem 3.4 3.4 0.6 1.6 2.8 7.548 198 P<0.001 
Pro social 5.8 4.5 9.5 2.1 3.7 8.088 198 P<0.001 
Externalizing Prob 8.7 8.6 1.1 4.1 7.6 7.977 198 P<0.001 
Internalizing prob 4.7 4.7 0.8 2.4 3.9 7.400 198 P<0.001 
Total S&D 13.4 13.2 1.9 6.4 11.5 7.842 198 P<0.001 
  
The table-8 states the comparisons of scores of Strength & 
Difficulties questionnaire with its components between the cases & 
controls. The mean scores of the subscales are as follows (cases vs 
controls): emotional problems (1.3±1.6 vs 0.2±0.9), conduct problems 
(3.9±3.9 vs 0.5±1.9), hyperactivity’ (4.8±4.8 vs 0.6±2.2), peer problem 
(3.4±3.4 vs 0.6±1.6),  and pro-social (5.8±4.5 vs 9.5±2.1). The difference 
between the two groups in all subscales were statistically very highly 
significant (P<0.001).  
The mean scores of the “externalising problems” subscale were 
8.7±8.6 for cases and 1.1±4.1 for controls. The difference between the two 
groups was statistically very highly significant (P<0.001). Similarly, the 
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mean scores of the “internalising problems” subscale were 4.7±4.7 for the 
cases and 0.8±2.4 for the controls. The difference of means between the two 
groups was statistically very highly significant (P<0.001). The total mean 
score of the questionnaire was 13.4±13.2 for the seizure group and 1.9±6.4 
for control group. The difference of means between the two groups was 
statistically very highly significant (P<0.001).  
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Table-9: Comparison of raw scores of SDQ between the Seizure group and 
control group: 
SDQ 
score Category 
Seizures control 
“Z” Sig 
No % No % 
0-13 Normal 53 53.0 94 94.0 
7.418 P<0.001 
14-16 Border line 1 1.0 0 0.0 
17-40 Abnormal 46 46.0 6 6.0 
Total 100 100.0 50 100.0 
  
The above table-9 states the comparison between the raw scores of 
SDQ between the 2 groups. The raw scores of SDQ showed that 53% of 
cases had normal scores, 46% had abnormal scores and 1% had scores in 
the borderline, whereas in the control group 94% had normal scores and 
only 6% had abnormal scores.The differences between them were 
statistically very highly significant (P<0.001). 
 
 
SDQ RAW SCORES- CASES & CONTROLS 
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Epileptic children on monotherapy (single AED) vs polytherapy 
(multiple AEDs): 
 The monotherapy group was administered with single drug- 
valproate and the polytherapy group was administered with multiple drugs. 
 
Table-10: Drugs administered to seizure groups: 
Name of the 
group 
No of 
drugs Name of the drugs 
Monotherapy Single 1.SVP 200 Mg 
Polytherapy Multiple 
1.SVP 200 Mg 
2.LEVITIRACETAM 250MG 
3.PHENOBARBITONE 
4.PHENYTOIN 100MG 
5.CARBAMAZEPINE 
6.CLOBAZAM 5MG 
7.CLONAZEPAM 
8.LEVITIRACETAM 250MG 
9. OXCARBAZEPINE 
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Table-11: Age and gender wise distribution of Mono & polytherapy 
groups: 
Age group 
(years) 
Monotherapy group Polytherapy group 
Male Female Male Female 
No % No % No % No % 
6-9 17 65.4 13 54.2 17 68.0 10 40.0 
10-12 9 34.6 11 45.8 8 32.0 15 60.0 
Total 26 100.0 24 100.0 25 100.0 25 100.0 
Mean 
±SD 8.9±1.7 8.8±1.7 8.8±1.7 9.7±1.5 
  
The table-11 gives the gender wise age distribution between the 
Mono & polytherapy groups. The mean ages of males and females of 
Monotherapy group were 8.9±1.7 years and 8.8±1.7 years. The mean ages 
of polytherapy group were 8.8±1.7 years and 9.7±1.5 years. 
62 
 
65.40%
54.20%
34.60%
45.80%
MALE FEMALE
AGE  & GENDER WISE DISTRIBUTION OF 
MONOTHERAPY GROUP
6-9 YEARS 10-12 YEARS
68.00%
40.00%
32.00%
60.00%
MALE FEMALE
AGE  & GENDER WISE DISTRIBUTION OF 
POLYTHERAPY GROUP
6-9 YEARS 10-12 YEARS
 
63 
 
Comparison of questionnaires between the Mono & polytherapy 
groups:  
 The questionnaires such as Developmental Coordination Disorder 
(DCD), 
Quality of Life in Childhood Epilepsy (QOLCE), Child behaviour checks 
list (CBCL) and strength and difficulty (SD) were compared between the 
Mono & polytherapy groups. 
Table-12: Comparison of DCDQ between Mono & polytherapy groups 
according to the ages: 
Age 
Years 
Monotherapy group Polytherapy group 
Suspected DCD No DCD Suspected DCD No DCD 
Score No % Score No % Score No % Score No % 
5-7 15-46 0 0.0 47-75 11 22 15-46 0 0.0 47-75 8 19 
8-9 15-55 0 0.0 56-75 19 38 15-55 1 2.0 56-75 18 38 
10+ 15-57 0 0.0 58-75 20 40 15-57 0 0.0 58-75 23 43 
Total 0 0.0 - 50 100 - 1 2.0 - 49 98.0 
Mean±SD 74.3±2.0 71.5±6.3 
“t” 2.945 
Significance P<0.01 
The table-12 compares the scores of DCDQ between the two groups. 
The mean DCD score of Monotherapy group was 74.3±2.0 and that of 
polytherapy group was 71.5±6.3. The difference between the means was 
statistically highly significant (P<0.01). 
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Table-13: Comparison of results of Quality of Life in Childhood Epilepsy 
(QOLCE) questionnaire between Monotherapy & polytherapy group: 
Variable 
Monotherapy Polytherapy Difference 
b/w means “t” df Sig Mean SD Mean SD 
QOLCE 62.6 28.3 48.2 31.6 14.5 2.410 98 P=0.018 
  
The above table -13 compares the scores of QOLCE questionnaire 
between the 2 groups. The mean QOLCE of Monotherapy group was 
62.6±28.3 and that of the polytherapy group was 48.2±31.6. The difference 
between the means of the two groups was statistically significant (P<0.05).  
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Table-14: Comparison of results of Child behaviour check list (CBCL) 
questionnaire between Monotherapy & polytherapy groups: 
 
Variable Monotherapy  Polytherapy Difference  
b/w means  
“t” df Sig 
Mean SD Mean SD 
CBCL 29.5 37.9 47.6 41.6 18.1 2.277 98 P=0.025 
  
The CBCL scores of 2 groups were compared in the above table-15. 
The mean CBCL score of Monotherapy group was 29.5±37.9 & that of  the 
polytherapy group was 47.6±41.6. The difference of means between the two 
groups was statistically significant (P<0.025) 
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Table-15: Comparison of raw scores of CBCL questionnaire between the 
Mono & polytherapy groups in the age group of   6-11 years: 
Groups CBCL Score 
Category 
No % Z Sig 
Monotherapy 
<38 
Normal 
26 60.5 
2.159 P<0.05 
39-48 
Border line 
0 0.0 
49+ 
Clinically. 
Significant 17 39.5 
Total 43 100.0 
Polytherapy 
<38 
Normal 
18 40.9 
39-48 
Border line 
0 0.0 
49+ 
Clinically. 
Significant 26 59.1 
Total 44 100.0 
 
Table-15 states the comparison between the 2 groups. (Age: 6-11 
years). In the monotherapy group, 60.5% had CBCL scores <38 and 39.5% 
had scores >49. In the polytherapy group, 40.9% had CBCL scores <38 and 
59.1% had scores >49. The differences between the two groups were 
statistically significant (P<0.05).   
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Table-16: Comparison of raw scores of CBCL questionnaire between the 
Mono & polytherapy groups in the age group of 12-18 years: 
Groups CBCL Score Category No % Z Sig 
Monotherapy 
<39 Normal 6 85.7 
0.814 P>0.05 
40-51 Border line 0 0.0 
52+ Clinically. Significant 1 14.3 
Total 7 100.0 
Polytherapy 
<39 Normal 4 66.7 
40-51 Border line 0 0.0 
52+ Clinically. Significant 2 33.3 
Total 6 100.0 
  
Table-16 states the comparison between the 2 groups. (Age: 12-18 
years). In the monotherapy group, 85.7% had CBCL scores <39 and 14.3% 
had scores >52. In the polytherapy group, 66.7% had CBCL scores <39 and 
33.3% had scores >52.  The differences between the two groups were 
statistically not significant (P>0.05).   
 
 
69 
 
0% 20% 40% 60% 80%
NORMAL
BORDERLINE
CLINICALLY 
SIGNIFICANT
CBCL SCORES OF MONO & POLYTHERAPY 
GROUPS (6-11 YEARS)
POLYTHERAPY GROUP
MONOTHERAPY 
GROUP
0% 20% 40% 60% 80% 100%
NORMAL
BORDERLINE
CLINICALLY 
SIGNIFICANT
CBCL SCORES OF MONO & POLYTHERAPY 
GROUPS (12-18 YEARS)
POLYTHERAPY GROUP
MONOTHERAPY 
GROUP
 
 
 
 
70 
 
Table-17: Comparison of results of Strength and Difficulty (SD) 
questionnaire with its components between mono & polytherapy groups: 
S&D Components 
Monotherapy Polytherapy Difference 
b/w means “t” df Sig Mean SD Mean SD 
Emotional 0.8 1.1 1.7 1.8 0.9 3.009 98 P=0.003 
Conduct 3.1 3.8 4.6 3.9 1.5 2.028 98 P=0.045 
Hyper activity 3.9 4.6 5.8 4.8 1.9 2.004 98 P=0.048 
Peer problem 2.8 3.2 4.1 3.6 1.3 1.944 98 P=0.055 
Pro social 6.7 4.2 5.0 4.6 1.7 1.933 98 P=0.056 
Externalizing Prob 7.0 8.4 10.4 8.6 3.4 2.024 98 P=0.046 
Internalizing prob 3.6 4.2 5.8 4.9 2.2 2.438 98 P=0.017 
Total S&D 10.5 12.5 16.2 13.4 5.7 2.183 98 P=0.013 
 
The table-17 states the comparisons of SDQ components between the 
two groups (Mono and polytherapy). The mean scores of ‘emotional 
problems’ subscale of two groups were 0.8±1.1 and 1.7±1.8 respectively 
and the difference between them was statistically highly significant 
(P<0.01). The mean scores of ‘conduct problems’ subscales were 3.1±3.8 
and 4.6±3.9. The difference between the two groups was statistically 
significant (P<0.05). The mean scores of ‘hyperactivity’ subscale were 
3.9±4.6 and 5.8±4.8. The difference between the means was statistically 
significant (P<0.05). The mean scores of ‘peer problem’ subscale of 
monotherapy group was 2.8±3.2 and that of polytherapy group was 4.1±3.6. 
The difference between them was statistically not significant (P>0.05). The 
mean scores of ‘pro social’ subscale of monotherapy group was   6.7±4.2 
and that of the polytherapy group was 5.0±4.6. The difference was 
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statistically not significant (P>0.05). The mean scores of “externalising 
problems” subscale (mono & polytherapy) were 7.0±8.4 and 10.4±8.6 
respectively. The difference between the two groups was statistically 
significant (P<0.05). Similarly, the mean scores of “internalising problems” 
subscale were 3.6±4.2 and 5.8±4.9. The difference between the two groups 
was statistically significant (P<0.05). The total mean SDQ score of 
monotherapy group was 10.5±12.5 and that of polytherapy group was 
16.2±13.4. The difference of means between the two groups was 
statistically significant (P<0.05).  
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Table-18: Comparison of raw scores of SDQ between the Mono and 
polytherapy group: 
 
SDQ 
score Category 
Monotherapy Polytherapy 
“Z” Sig 
No % No % 
0-13 Normal 31 62.0 22 44.0 
1.833 P>0.05 
14-16 Border line 1 2.0 0 0.0 
17-40 Abnormal 18 36.0 28 56.0 
Total 50 100.0 50 100.0 
 
 The above table-18 states the comparison of raw scores of SDQ 
between the 2 groups. The raw scores of SDQ showed that 62% of 
monotherapy group had normal scores,36% had abnormal scores and 2% 
had scores in the borderline, whereas in the polytherapy group 44% had 
normal scores and 56% had abnormal scores.The differences between them 
were not statistically significant (P>0.05).  
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Table-19: Comparison of types of seizures between the groups’ 
monotherapy and polytherapy: 
Types of 
Seizure 
MONOTHEARPY POLYTHERAPY Total 
χ2 df Sig 
No % No % No % 
Convulsive 
Status 
Epilepticus 
8 16.0 24 48.0 32 32.0 
21.783 2 P<0.001 
GTCS 23 46.0 24 48.0 47 47.0 
Partial 19 38.0 2 4.0 21 21.0 
Total 50 100.0 50 100.0 100 100.0 
 
The above table-19 shows the type of seizures between the 2 groups. 
16% had convulsive status epilepticus in the monotherapy group as against 
48% in the polytherapy group. 46% in the monotherapy group had GTCS as 
against 48% in the polytherapy group.38% had partial seizures in the 
monotherapy group as against only 4% in the polytherapy group. 
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Table-20: Comparison of age at onset of seizure between the Mono and 
polytherapy groups: 
 
With respect to the age of onset of seizures, the mean age at onset 
was 6.2±2.4 years for monotherapy group and 5.3±2.2 years for polytherapy 
group. The difference of age between the two groups was statistically 
significant (P<0.05) 
  
 
 
  
Age 
(years) 
Monotherapy Polytherapy Difference 
b/w means 
“t” df Sig 
Mean SD Mean SD 
Seizure on set 6.2 2.4 5.3 2.2 0.9 2.140 98 P=0.035 
77 
 
0-1 YEAR
1-2 YEARS
>2 YEARS
0%
10%
20%
30%
40%
50%
60%
0-1 YEAR
1-2 YEARS
>2 YEARS
Table-21: Comparison of duration of seizures between the mono & 
polytherapy groups: 
Duration 
(years) 
Monotherapy Polytherapy Total 
χ2 df Sig 
No % No % No % 
0-1 3 6.0 11 22.0 14 14.0 
5.851 2 P=0.054 
1-2 18 36.0 18 36.0 36 36.0 
2+ 29 58.0 21 42.0 50 50.0 
Total 50 100.0 50 100.0 100 100.0 
Comparison of mean duration of seizures showed that 6% children 
had seizures for 0-1 years in the monotherapy group as against 22% in the 
polytherapy group.36% children had seizures for 1-2 years in both the mono 
& polytherapy groups.58% children had seizures for more than 2 years in 
monotherapy group as against 42% in the polytherapy group 
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Table-22: Comparison of frequency of seizures between the mono & 
polytherapy groups: 
Frequencies 
Monotherapy Polytherapy Total 
χ2 df Sig 
No % No % No % 
Rarely 23 46.0 11 22.0 34 34.0 
8.292 2 P=0.016 
Monthly 6 12.0 15 30.0 21 21.0 
Yearly 21 42.0 24 48.0 45 50.0 
Total 50 100.0 50 100.0 100 100.0 
Comparison of seizure frequencies showed that 46% children in the 
monotherapy group had seizures occurring rarely as against 22% in the 
polytherapy group. 12% children had at least monthly 1 episode of seizure 
in the monotherapy group as against 30% in the polytherapy group. 42% 
children had at least 1 episode of seizure per year in the monotherapy group 
as against 48% in the polytherapy group. The differences between the 2 
groups in seizure frequencies were statistically significant (P<0.05) 
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Table-23 Comparison of last episode of seizure between the mono & 
polytherapy groups: 
Last Episodes 
(years) 
Monotherapy Polytherapy Total 
χ2 df Sig 
No % No % No % 
0-1 11 22.0 21 42.0 32 32.0 
7.323 2 P=0.026 
1-2 19 38.0 20 40.0 39 39.0 
2+ 20 40.0 09 18.0 29 18.0 
Total 50 100.0 50 100.0 100 100.0 
 
Comparison of last episode of seizure showed that 22% had seizures 
in the last 0-1 years in the monotherapy group as against 42% in the 
polytherapy group. 38% had seizures in the last 1-2 years in the 
monotherapy group as against 40% in the polytherapy group.40% children 
had seizures >2 years ago in the monotherapy group as against only 18% in 
the polytherapy group. The differences between the two groups in terms of 
last episode of seizures were statistically significant (P<0.05). 
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Table-24 Comparison of the duration of drug intake between the mono & 
polytherapy groups: 
Drug 
(years) 
Monotherapy Polytherapy Difference  
b/w means  
“t” df Sig 
Mean SD Mean SD 
Duration 2.8 1.4 4.0 1.9 1.2 3.463 98 P=0.001 
 
Comparison of the duration of drug intake showed that the mean 
drug duration of monotherapy group was 2.8±1.4 years as against 4.0±41.9 
in the polytherapy group. The difference of means between the two groups 
was statistically significant (P<0.01) 
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DISCUSSION 
A total of 200 children in the age group of 6-12 years were included 
in the study (100 cases and 100 age and sex matched controls). Among the 
100 cases, 50 were on single AED-valproate (Monotherapy group) and 
another 50 were on multiple AEDs (Polytherapy group). All children 
recruited into the study (fulfilling the inclusion criteria) were administered 
the following questionnaires: DCDQ, QOLCE, CBCL, and SDQ 
questionnaires and the scores of them were compared between the cases and 
controls and also between the mono & polytherapy groups. Additionally, 
the age of onset, the type of seizures, the frequency, duration, and age at last 
episode, and the mean drug duration was compared within the seizure 
groups. 
Age distribution: Out of 100 cases, 57% were in the 6-9 years age 
group and 43% were in the 10-12% age group. Similarly, out of 100 
controls, 57% were in the 6-9 years age group and 43% were in the 10-12% 
age group. The mean ages of both the groups were 9.2±1.7 years. 
Gender distribution: Out of 100 cases, 51 % of the children were 
males and 49% were females. Similarly, out of 100 controls, 51 % were 
males and 49% were females. 
Comparison of age and gender wise distribution between the cases 
and controls showed that the mean ages of males and females in both the 
groups were 8.8±1.7 years and 9.5±1.8 years.  
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The scores of DCD questionnaire showed that only 1 out of 100 
cases fall in the ‘suspected DCD group’, and the remaining 99 fall in the 
‘No DCD group’. All controls fall in the ‘No DCD group’.The mean DCD 
of seizure group was 72.9±4.9. The mean DCD of control group was 
74.8±1.2. The difference between the means was statistically very highly 
significant (P<0.001), stating that the possibility of developmental 
coordination disorder is higher in the seizure group than the control group. 
In a study done by Stuart D.W.Smith et al, it was shown that the possibility 
of DCD was higher in children with Rolandic epilepsy than the controls [27]. 
 The scores of QOLCE questionnaires showed that the mean QOLCE 
of seizure group was 55.4±30.7 and the same of the control group was 
84.3±13.5. The difference between the means of the two groups was 
statistically very highly significant (P<0.001), stating that the quality of life 
is worse in seizure group (lower scores) than the control group as higher 
scores are associated with higher well-being. This result was similar to the 
study done by Nagesh adla et al in which the mean overall QOL score of 
104 children aged 4-13 years was 46.82 ± 10.90 and hence concluded that 
children with epilepsy have a comparatively poorer quality of life. [24] 
 The scores of CBCL questionnaires showed that the mean CBCL of 
seizure group was 38.6±40.6. The mean CBCL of control group was 
5.4±20.6. The difference of means between the two groups was statistically 
very highly significant (P<0.01).This result was similar to the study done by 
Om P Mishra et al in which the mean CBCL scores of cases were 
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significantly higher than controls [22]. In the age group of 6-11 years, it was 
found that 50.6% of children in the seizure group had normal CBCL scores, 
whereas 49.4% of children had abnormal scores (Scores >49 in 6-11 years 
group and >52 in 12-18 years group are considered abnormal). In the 
control group 93.1% of children had normal scores whereas only 6.9% had 
abnormal scores.The differences between the two groups were statistically 
very highly significant (P<0.05).  In the age group of 12-18 years, 76.9% of 
children in the seizure group had normal CBCL scores, whereas 23.1% of 
children had abnormal scores. In the control group all children had normal 
scores (100%).The differences between the two groups were statistically 
significant (P<0.05).A similar result was also observed in a study done by 
Michael Freilinger et al in which 108 children with epilepsy aged 5 to 18 
years were applied CBCL questionnaire and 22.2% had abnormal scores[25]. 
Hence our study shows that children in the seizure group have more 
clinically significant abnormal behavior (higher scores are associated with 
abnormal behavior) than the control group.   
 The analysis of results of SDQ questionnaire showed that the mean 
scores (cases vs controls) of emotional (1.3±1.6 vs 0.2±0.9), conduct 
(3.9±3.9 vs 0.5±1.9), hyperactivity (4.8±4.8 vs 0.6±2.2), and peer problem 
(3.4±3.4 vs 0.6±1.6) scales were higher in the seizure group than the control 
group (statistically very highly significant- P<0.001).On the other hand, the 
mean pro-social scores (5.8±4.5 vs 9.5±2.1) were higher in the control 
group, which was statistically very highly significant (P<0.001).The raw 
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scores of SDQ showed that 53% of cases had normal scores, 46% had 
abnormal scores and 1% had scores in the borderline, whereas in the control 
group 94% had normal scores and only 6% had abnormal scores.The 
differences between them were statistically very highly significant 
(P<0.001).Hence, our study shows that emotional problems, conduct 
problems, hyperactivity and peer problems are more common in the seizure 
group than the control population based on the SDQ scores. A similar result 
was published in the study done by Modage Anita et al [8]. 
 The possibility of developmental coordination disorder, poorer 
quality of life, clinically significant abnormal behaviors, and emotional/ 
conduct/ hyperactivity/ peer problems are more common in the seizure 
group than the control group. 
 The seizure group was divided into 2 groups – Monotherapy group 
(single AED- valproate) and polytherapy group (multiple AEDs) and were 
compared. 
 Comparison of age and gender wise distribution between the 2 
groups showed that the mean ages of males and females of monotherapy 
group were 8.9±1.7 years and 8.8±1.7 years respectively. The mean ages of 
males and females of polytherapy group were 8.8±1.7 years and 9.7±1.5 
years respectively. 
The scores of DCD questionnaire showed that only 1 out of 50 
children in polytherapy group fall in the ‘suspected DCD’ group and the 
remaining 49 fall in the ‘No DCD’ group. All children in the monotherapy 
85 
 
group fall in ‘No DCD group’. The mean DCD of monotherapy group was 
74.3±2.0. The mean DCD of polytherapy group was 71.5±6.3. The 
difference between the means was statistically highly significant (P<0.01), 
stating that the possibility of developmental coordination disorder is higher 
in the polytherapy group (lower scores are associated with DCD) than the 
monotherapy group. 
The scores of QOLCE questionnaires showed that the mean QOLCE 
of monotherapy group was 62.6±28.3 and the same of the polytherapy 
group was 48.2±31.6. The difference between the means of the two groups 
was statistically significant (P<0.05), stating that the quality of life is worse 
in polytherapy group (lower scores) than the monotherapy group as higher 
scores are associated with higher well-being. This was similar to the results 
of the study done by JayashreeNadkarni et al in which poorer QOL was 
observed in children receiving polytherapy [26]. 
 The scores of CBCL questionnaires showed that the mean CBCL of 
monotherapy group was 29.5±37.9. The mean CBCL of polytherapy group 
was 47.6±41.6. The difference of means between the two groups was 
statistically significant (P<0.5). In the age group of 6-11 years, it was found 
that 60.5% of children in the monotherapy group had normal CBCL scores, 
whereas 39.5% of children had abnormal scores. In the polytherapy group 
40.9% of children had normal scores whereas 59.1% had abnormal 
scores.The differences between the two groups were statistically significant 
(P<0.05).  In the age group of 12-18 years, 85.7% of children in the 
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monotherapy group had normal CBCL scores, whereas 14.3% of children 
had abnormal scores. In the polytherapy group 66.7% children had normal 
scores whereas 33.3% had abnormal scores.The differences between the 
two groups were not statistically significant (P>0.05). Hence, children in 
the polytherapy group have more clinically significant abnormal behavior 
(higher scores are associated with abnormal behavior) than the monotherapy 
group based on the CBCL scores. A similar result was also observed in the 
study done by Amir A. Sarhan et al [14]. 
 The analysis of results of SDQ questionnaire showed that the mean 
scores (monotherapy group vs polytherapy group) of emotional (0.8±1.1 vs 
1.7±1.8), conduct (3.1±3.8 and 4.6±3.9), hyperactivity (3.9±4.6 and 
5.8±4.8), and peer problem (2.8±3.2 vs 4.1±3.6) scales were higher in the 
polytherapy group than the monotherapy group. The difference in scores of 
emotional (P<0.01), conduct(P<0.05), hyperactivity(P<0.05) scales between 
the 2 groups was statistically significant, whereas in the case of peer 
problem scale (P>0.05),it was not statistically significant. On the other 
hand, the mean pro-social scores (6.7±4.2 vs 5.0±4.6) were higher in the 
monotherapy group, which was not statistically significant (P>0.05).The 
raw scores of  SDQ showed that 62% of monotherapy group had normal 
scores, 36% had abnormal scores and 2% had scores in the borderline, 
whereas in the polytherapy group 44% had normal scores and 56% had 
abnormal scores.The differences between them were not statistically 
significant (P>0.05). Hence, our study shows that emotional problems, 
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conduct problems, and hyperactivity problems are more common in the 
polytherapy group than the monotherapy group population based on the 
SDQ scores.Tanabe T1et al in their study observed a similar result [23] 
Comparison of types of seizures between the mono & polytherapy 
groups showed that 16% had convulsive status epilepticus in the 
monotherapy group as against 48% in the polytherapy group. 46% in the 
monotherapy group had GTCS as against 48% in the polytherapy 
group.38% had partial seizures in the monotherapy group as against only 
4% in the polytherapy group. Hence, our study shows that convulsive status 
epilepticus and GTCS were common in the polytherapy group whereas 
partial seizures were more common in the monotherapy. 
 Comparison of age at onset of seizure between the mono & 
polytherapy groups showed that the mean age at onset was 6.2±2.4 years for 
monotherapy group and 5.3±2.2 years for polytherapy group. The 
difference of age between the two groups was statistically significant 
(P<0.05), stating that the children in the polytherapy group had an early 
onset of seizures than the monotherapy group. 
 Comparison of mean duration of seizures showed that 6% children 
had seizures for 0-1 years in the monotherapy group as against 22% in the 
polytherapy group.36% children had seizures for 1-2 years in both the mono 
& polytherapy groups.58% children had seizures for more than 2 years in 
monotherapy group as against 42% in the polytherapy group 
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Comparison of seizure frequencies showed that 46% children in the 
monotherapy group had seizures occurring rarely as against 22% in the 
polytherapy group. 12% children had at least monthly 1 episode of seizure 
in the monotherapy group as against 30% in the polytherapy group. 42% 
children had at least 1 episode of seizure per year in the monotherapy group 
as against 48% in the polytherapy group. The differences between the 2 
groups in seizure frequencies were statistically significant (P<0.05), stating 
that the children in the polytherapy group have more frequent seizures than 
the monotherapy group. 
 Comparison of last episode of seizure showed that 22% had seizures 
in the last 0-1 years in the monotherapy group as against 42% in the 
polytherapy group. 38% had seizures in the last 1-2 years in the 
monotherapy group as against 40% in the polytherapy group.40% children 
had seizures >2 years ago in the monotherapy group as against only 18% in 
the polytherapy group. The differences between the two groups in terms of 
last episode of seizures were statistically significant (P<0.05), again stating 
that the children in the polytherapy group had more frequent seizures than 
the monotherapy group. 
 Comparison of the duration of drug intake showed that the mean 
drug duration of monotherapy group was 2.8±1.4 years as against 4.0±41.9 
in the polytherapy group. The difference of means between the two groups 
was statistically significant (P<0.01), stating that children in the 
polytherapy have been taking AEDs for longer duration than the 
monotherapy group. 
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 The possibility of developmental coordination disorder, poorer 
quality of life, clinically significant abnormal behaviors, and emotional/ 
conduct/ hyperactivity problems are more common in the polytherapy 
group (multiple AEDs) than the monotherapy group (single AED). Also, 
Convulsive status epilepticus/GTCS, seizure profile-early onset/ longer 
duration/ increased frequency and longer duration of drug therapy are more 
common in the polytherapy group (multiple AEDs) than the monotherapy 
group (single AED). 
 Neurobehavioral comorbidities are common in children with seizure 
disorder than the general population. These were consistent with the results 
of the studies done by Charles J.Kind et al[9], Kari ModalsliAaberg et al10], 
Ahyuda et al[16]. Furthermore, they are more common in children who are 
on multiple AEDs for longer duration with the seizures being CSE/GTCS 
type, earlier in age of onset, for longer duration and are frequently 
recurring. These were similar to the results of studies done by Amir A. 
Sarhan et al[14] and Om P Mishra et al[22]. 
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CONCLUSION 
 Neurobehavioral comorbidities are common in children with 
epilepsy than the general population.  
 Children who are on multiple anti-epileptic drugs for longer duration 
are more vulnerable to these comorbidities than those on 
monotherapy. 
 Early age of onset, increased frequency of seizures and increased 
duration of epilepsy are found to significantly affect the 
neurobehavioral outcome. 
 Questionnaires like Strength & difficulties questionnaire (SDQ), 
Quality of life in childhood epilepsy questionnaire (QOLCE), Child 
behaviour checklist questionnaire (CBCL), and Developmental 
Coordination disorder questionnaire (DCDQ) can be used to screen 
these comorbidities. 
 Based on their scores, children with epilepsy (Polytherapy> 
monotherapy) are at increased risk of developing behavioural and 
emotional problems, conduct and hyperactivity problems, 
developmental coordination disorder and hence have a poorer quality 
of life. 
 These comorbidities may often affect the family life, friendships and 
classroom learning. 
 When these are unattended, they may lead to school dropouts, 
irregularity and ultimately poor life outcomes. 
 Therefore, screening of all children with epilepsy for cognitive & 
behavioural difficulties becomes mandatory and it should be 
incorporated in the management in childhood seizures. 
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STUDY LIMITATIONS 
 The study did not take into account the family-related factors (family 
stress factors, family dynamics, and parent/child relationship) and 
personality traits that may have contributed to some degree of 
psychopathology in epileptic children. 
 The effects of individual drugs on the neurobehavioral outcomes 
were not assessed separately. 
 Questionnaires that are used in the study are only a screening test 
and hence further confirmation of the disorder/disease needs 
evaluation by a child psychiatrist. 
 Separate IQ assessment was not done and it was indirectly assessed 
using the questionnaires. 
. 
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ANNEXURES 
 
ABBREVIATIONS 
 AED – Anti Epileptic Drug 
 DCDQ – Developmental Coordination Disorder Questionnaire 
 QOLCE- Quality Of Life in Childhood Epilepsy questionnaire 
 CBCL-Child Behaviour Check List questionnaire  
 SDQ-Strength and Difficulties Questionnaire 
 ADHD-Attention Deficit Hyperactivity Disorder 
 ASD-Autism Spectrum Disorder 
 ASQ-Autism Screening Questionnaire 
 EEG- Electroencephalography 
 ILAE- International League of Association of Epilepsy 
 IEM- Inborn Error of Metabolism 
 GERD-Gastro Esophageal Reflux Disease 
 ICP-Intra Cranial Pressure 
 GTCS-Generalized Tonic Clonic Seizures 
 CSE-Convulsive Status Epilepticus 
 LGS- Lennox-Gastaut syndrome 
 CAE-Childhood Absence Epilepsy 
 CPS-Complex Partial Seizures 
 JME-Juvenile Myoclonic Epilepsy 
 SVP-Sodium Valproate 
 LEV-Levetiracetam 
 CBZ-Carbamazepine 
  
 
 
DATA COLLECTION FORM 
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PATIENT INFORMATION SHEET 
Place of study: Institute Of Child Health And Hospital for Children,  
Egmore, Chennai-8. 
Name of Investigator: DR.RAMESH KRISHNAN.B 
Name of Participant:    Age:   Sex:  
Hospital No:      
Study title 
  We request your child to participate in the study. 
Aim of the study –  
  To compare the clinical & neurobehavioral profile of children with  
seizure disorder  versus healthy controls in a tertiary health care centre 
Methods- 
  This study aims at comparing the neurobehavioral comorbidities in 
children with seizure disorder versus healthy controls using questionnaires 
& confirmation will be performed by child psychiatrist 
Can I refuse to participate in the study? 
 Participation in the study is purely voluntary. You may refuse to 
participate or withdraw from the study at any time. In both cases the 
treatment and care your child receives from this hospital will not be affected 
in any manner. 
Benefits and harms of participating in the study- 
 Your child will not benefit directly by participating in this study. But 
by way of participating in this study, your child is contributing to 
 
 
information which when compiled, will yield useful information and will 
help in early identification and treatment to reduce the distress associated 
with the condition. 
Confidentiality- 
 The data collected from the study will be used for the purpose of 
study only. The results of the study will be published. Personal information 
of the children and parents participating in the study will be kept 
confidential. There will not be any disclosure about your child’s 
information without your permission. 
Subject rights- 
 If you wish further information regarding your child’s rights as a 
research participant, you may contact the principal investigator in the 
mobile number or addressmentioned below. 
 
Principal Investigator - Dr.RAMESH KRISHNAN.B 
Mobile number  - 9940781752 
Contact Address  - Post graduate of Paediatrics, 
Institute of Child Health and Hospital for 
Children, Halls road, Egmore, Chennai. 
 
Place:  
Date:        Signature of Parent 
 
 
 
INFORMED CONSENT FORM 
Study place : Institute Of Child Health And Hospital For Children,   
Egmore,Chennai-8. 
Title of the study: 
 A COMPARATIVE STUDY OF THE CLINICAL & 
NEUROBEHAVIORAL PROFILE OF CHILDREN WITH SEIZURE 
DISORDER Vs HEALTHY CONTROLS IN A TERTIARY HEALTH 
CARE CENTRE 
Name of the investigator : Dr.RAMESH KRISHNAN.B   
Name of the Participant :  Age:   Sex: 
Hospital number:   
1. I have read and understood the patient information sheet provided to me 
regarding the participation of my child in the study.  
2. I have been explained about the nature of the study and had my 
questions answered to my satisfaction.  
3. I have been explained about my rights and responsibilities by the 
investigator. 
4. I will allow my child tocooperate with the investigatorand undergo 
clinical tests subjected during the study whole heartedly. 
5. I have been advised about the risks associated with my child’s 
participation in this study.* 
6. I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my child’s future 
treatment in this hospital. * 
7. I hereby give permission to the investigators to release the information 
obtained from my child as result of participation in this study to medical 
journals/conference proceedings. 
 
 
8. I understand that my child’s identity will be kept confidential if my 
child’s data are publicly presented/published. 
9. I have decided my child can participate in the research study. I am aware 
that if I have any question during this study, I should contact the 
investigator.  
10. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will 
be given a copy of this consent document. 
 
Name and signature / thumb impression of the parent/guardian  
Name  _________________________ Signature ________________   
Date ________________  
 
Name and Signature of the investigator  
Name  _________________________ Signature ________________   
Date ________________  
 
Name and Signature of impartial witness 1:  
Name  _________________________ Signature ________________   
Date ________________  
 
Name and Signature of impartial witness 2:  
Name  _________________________ Signature ________________   
Date ________________  
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